Next-generation sequencing–based posttransplant monitoring of acute myeloid leukemia identifies patients at high risk of relapse

Tae‐Hyung Kim; Joon Ho Moon; Jae-Sook Ahn; Yeo‐Kyeoung Kim; Seung-Shin Lee; Seo-Yeon Ahn; Sung‐Hoon Jung; Deok‐Hwan Yang; Je‐Jung Lee; Seung Hyun Choi; Ja-Yeon Lee; Marc S. Tyndel; Myung‐Geun Shin; Yoo Jin Lee; Sang Kyun Sohn; Seong-Kyu Park; Zhaolei Zhang; Hyeoung‐Joon Kim; Dennis Dong Hwan Kim

doi:10.1182/blood-2018-04-848028

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

< .001), independent of the revised European LeukemiaNet risk groups. Overall, current study demonstrates that NGS-based posttransplant monitoring in AML patients is feasible and can distinguish high-risk patients for relapse.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Kim et al. (2018) studied this question.

synapsesocial.com/papers/6a10629e90ecb39bf65fdb47 https://doi.org/10.1182/blood-2018-04-848028

View Full Paper

Ask AI

Bookmark

Share

Next-generation sequencing–based posttransplant monitoring of acute myeloid leukemia identifies patients at high risk of relapse

Ask about this paper

Abstract

Discussion

Cite This Study

Next-generation sequencing–based posttransplant monitoring of acute myeloid leukemia identifies patients at high risk of relapse

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading